Blood-based Biomarker Discovery Service
Biomarkers play a critical role in the cancer early detection and diagnosis. Among various sources for biomarker identification, blood-based biomarkers have gained significant attention due to their non-invasive nature and potential for widespread application. At Alfa Cytology, we offer a comprehensive suite of services for blood-based biomarker discovery in cancer research.
Overview of Blood-based Biomarker Discovery in Cancer Research
Biomarkers, which are measurable indicators of biological processes or disease states, can provide valuable insights into the underlying mechanisms of cancer and aid in personalized medicine approaches. Blood-based biomarker discovery focuses on analyzing various components present in blood samples, such as circulating tumor DNA (ctDNA), exosomes, and proteins, to identify potential biomarkers.
Fig.1 Schematic of the origin of cell-free DNA (cfDNA), circulating tumor cells (CTCs), and exosomes in the blood. (Marrugo-Ramírez J, et al., 2018)
ctDNA
ctDNA is fragmented DNA released into the bloodstream by tumor cells undergoing apoptosis or necrosis. It carries genetic alterations specific to the tumor and provides a non-invasive window into the tumor's molecular landscape.
Exosomes
Exosomes are small vesicles released by cells, including tumor cells, that contain various biomolecules, such as RNA, DNA, proteins, and lipids. These vesicles play a crucial role in intercellular communication and are found abundantly in biofluids, including blood.
Protein Biomarkers
Proteins are essential players in cellular processes and often dysregulated in cancer. Blood-based biomarker discovery involves the analysis of proteins present in the bloodstream to identify cancer markers.
Our Services
At Alfa Cytology, we offer a comprehensive suite of services designed to accelerate blood-based biomarker discovery in cancer research. Our services encompass the entire biomarker discovery pipeline, from sample collection to data analysis, ensuring a streamlined and efficient process. Our services include, but are not limited to:
Unveiling the Transcriptomic Landscape
By employing the technique of sequencing the entire RNA content, we can support our clients in various ways, including the identification of novel biomarkers, the investigation of alternative splicing events, the detection of fusion transcripts, and the exploration of non-coding RNA signatures.
Uncovering the Proteomic Signature
Alfa Cytology leverages mass spectrometry techniques to comprehensively profile the proteomic landscape of blood samples. Through quantitative analysis, we can identify differentially expressed proteins, post-translational modifications, and protein-protein interactions associated with cancer biology.
Decoding Metabolic Alterations
Alfa Cytology utilizes metabolomics approaches, liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy, to comprehensively profile the metabolome and identify metabolites specific to cancer phenotypes.
Data Analysis and Integration
Our skilled team of bioinformaticians and data scientists extract meaningful insights from complex multi-omics datasets. By integrating transcriptomic, proteomic, and metabolomic data, we unravel the intricate molecular landscape underlying cancer development and progression.
Our Advantages
Largest Toolbox
Strong Expertise
One-stop Solution
Short Turnaround
At Alfa Cytology, we are committed to advancing cancer research through our blood-based biomarker discovery services. Through our comprehensive solutions, advanced technologies, and experienced team, we enable researchers to unlock the potential of the blood proteome in unraveling the complexities of cancer. If you are interested in our service, please contact us for more details.
Reference
- Marrugo-Ramírez, et al.; (2018). Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. International journal of molecular sciences, 19(10), 2877.
For research use only.
Related Services
